A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease.

Nakamura, Yu; Strohmaier, Christine; Tamura, Kaoru; Kataoka, Naoko; Nakano, Masayuki; Oda, Shoichiro; Nishimura, Kazuma; Homma, Akira

Nakamura, Yu; Strohmaier, Christine; Tamura, Kaoru; Kataoka, Naoko; Nakano, Masayuki; Oda, Shoichiro; Nishimura, Kazuma; Homma, Akira.

Afiliação

Nakamura Y; Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Strohmaier C; Novartis Pharma AG, Basel, Switzerland.
Tamura K; Novartis Pharma K.K., Tokyo, Japan.
Kataoka N; Novartis Pharma K.K., Tokyo, Japan.
Nakano M; Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Oda S; Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Nishimura K; Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Homma A; Dementia Care Research and Training Center, Tokyo, Japan.

Dement Geriatr Cogn Dis Extra ; 5(3): 361-74, 2015.

Article em En | MEDLINE | ID: mdl-26557135